pharmaceuticals
pharmaceuticals Articles
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
Published:
Last Updated:
Biopharmaceutical company Zai Lab intends to price its 8 million shares in the range that results in an initial public offering valued up to more than $165 million.
Published:
Last Updated:
Alnylam Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm gave an update on its late-stage trial in patients with hereditary ATTR amyloidosis with polyneuropathy.
Published:
Last Updated:
Dimension Therapeutics saw one of the largest gains on the day after it came to light that the firm received an acquisition offering from Ultragenyx Pharmaceutical.
Published:
Last Updated:
Deciphera Pharmaceuticals expects to price more than 6 million shares in a range that results in an initial public offering valued up to more than $122 million.
Published:
Last Updated:
Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day.
Published:
Last Updated:
Array BioPharma saw its shares turn negative early on Thursday after the firm announced a secondary offering.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
BioCryst Pharmaceuticals watched its shares fall handily on Tuesday after the firm announced a secondary offering.
Published:
Last Updated:
Clinical-stage biopharmaceutical company Deciphera Pharmaceuticals has amended its filing with the SEC regarding its initial public offering.
Published:
Last Updated:
Often companies that lose their way or face adversity may need a change at the top. Teva Pharmaceutical seems to be the perfect example, and with its change investors are sending the shares much...
Published:
Last Updated:
Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder.
Published:
Last Updated:
Achillion Pharmaceuticals saw its shares slump early on Monday after the firm announced that its hepatitis C license and collaboration agreement with Janssen had been terminated.
Published:
Last Updated:
A new study from Princeton University indicates many prime-age men are no longer in the labor force because of a serious health condition, a factor that may help explain the decline in the labor...
Published:
Last Updated:
Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case Bristol-Myers Squibb is bucking that trend and investors are thrilled.
Published:
Last Updated: